United Kingdom Archives

cancer dna damage repair duke street bio parp

News and Trends 25 May 2022

Duke Street Bio enters stage with next-generation cancer therapies

The UK startup Duke Street Bio has exited stealth mode with funding to develop PARP enzyme inhibitors that treat cancer by blocking the repair of DNA in tumor cells. London-based Duke Street Bio said Tuesday that it has a portfolio of PARP1 and PARP7 enzyme inhibitors and has raised enough cash to fund its pipeline […]

May 25, 2022 - 3 minutesmins - By Susannah Rodgers

News and Trends 19 May 2022

F2G enlists Shionogi to bring antifungal treatment to Europe and Asia

The UK company F2G Ltd. has announced a strategic collaboration with Japanese pharmaceutical company Shionogi & Co. Ltd. to develop and commercialize olorofim, an antifungal treatment for invasive fungal infections, in Europe and Asia. The deal centers on olorofim, F2G’s oral antifungal therapy for the treatment of invasive aspergillosis, an infection that can be deadly […]

May 19, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 12 May 2022

The Top European Biotech Investments in April 2022

Private biotech investments in Europe were on a steady decline in April 2022 as biotech public markets continued to disappoint. The top funding rounds were dominated by UK and Swiss firms targeting genetic diseases and cancer. April 2022 provided no relief for the European biotech industry as public stock markets remain anemic. Though flush with […]

May 12, 2022 - 4 minutesmins - By Jonathan Smith

News and Trends 5 May 2022

Amphista Lands Megadeals to Smash Cancer using Protein Degradation

As big pharma companies flock to drugs that destroy harmful proteins, the UK protein degradation specialist Amphista Therapeutics has bagged two landmark collaboration deals with the heavyweights Bristol Myers Squibb and Merck. Big pharma companies are piling onto biotechs developing drugs that can cause the destruction of target proteins in the cell — a field […]

May 5, 2022 - 3 minutesmins - By Jonathan Smith

stephanie bewick destiny pharma chief business officer

Expert Advice 2 May 2022

Chief Business Officers: Shedding Light on Biotech’s Dealmakers

In addition to helping patients, biotech companies need to focus on the commercial potential of their work. Stephanie Bewick at Destiny Pharma outlines her experiences of how a Chief Business Officer maximizes their company’s commercial appeal and lands deals in the biotech industry. Stephanie Bewick began her career as an academic researcher before spending more […]

May 2, 2022 - 5 minutesmins - By Victor Kotsev

News and Trends 29 Apr 2022

Denmark Recruits Lifebit to Boost Personalized Medicine with Genomics

The Danish National Genome Center has teamed up with the UK firm Lifebit to improve the access and sharing of genomic data as the nation moves towards the adoption of personalized medicine. Personalized medicine is capturing the attention of healthcare authorities across the world. By harvesting genome sequences from patient populations, researchers can mine vast […]

April 29, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 28 Apr 2022

OMass Therapeutics Takes on ‘Undruggable’ Proteins with €90M Series B

The UK firm OMass Therapeutics has unveiled a €90M (£75.5M) Series B financing to bankroll the development of small molecules against so-called ‘undruggable’ targets, including one that sank Quench Bio last year. In 2020, Quench Bio captured the imagination of investors with the US firm’s ambition to develop a new class of anti-inflammatory drugs. The […]

April 28, 2022 - 3 minutesmins - By Jonathan Smith

cardiovascular disease heart attack forcefield therapeutics

News and Trends 25 Apr 2022

Forcefield Therapeutics Launched to Treat Heart Attacks with Protein Drugs

The startup Forcefield Therapeutics has been unveiled in the UK with €6M (£5.5M) backing from the investment firm Syncona. The mission is to develop the first drugs to safeguard heart muscle from damage during heart attacks. A sudden heart attack, also known as acute myocardial infarction, happens when the flow of blood to the heart […]

April 25, 2022 - 4 minutesmins - By Jonathan Smith

Guy Levy Yurista Synthace cloud computing 1

Opinion 25 Apr 2022

Cloud Computing Can Help Life Sciences Catch Up Before It’s Too Late

Biotechnology has the power to tackle global threats such as pandemics and climate change, but antiquated experimental and data collection methods are holding it back. Guy Levy-Yurista, CEO of the experiment platform developer Synthace, explains how cloud computing could accelerate the efforts of biotech companies to solve the big problems. There is a sundial in […]

April 25, 2022 - 5 minutesmins - By External Contributor

News and Trends 20 Apr 2022

Valneva’s Covid-19 Vaccine Reaches UK Market with EU In Sights

A Covid-19 vaccine developed by the French company Valneva has received the green light from the UK’s drug regulator. The EMA, meanwhile, is proving harder to convince. The UK’s relationship with the French vaccine developer Valneva has run hot and cold over the past two years. In 2020, the UK government invested in Valneva’s manufacturing […]

April 20, 2022 - 4 minutesmins - By Jonathan Smith

UK kynos epidarex anti inflammatory drugs

News and Trends 8 Apr 2022

Epidarex Backs UK Startup Developing Emerging Anti-Inflammatory Drugs

The UK-US venture capitalist Epidarex Capital has led an €11M (£9M) funding round raised by the Edinburgh-based Kynos Therapeutics, which aims to develop anti-inflammatory treatments by blocking an emerging metabolic target. Much of the UK’s biotech innovation is concentrated in the so-called Golden Triangle, encompassing the hubs of Cambridge, Oxford, and London. In 2020, Epidarex […]

April 8, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 6 Apr 2022

Immunocore Approvals Open Door for TCR Cancer Drugs

The EU has followed the FDA in granting market approval to Kimmtrak, the first-ever bispecific drug based on a cancer-hunting protein called a T-cell receptor (TCR). These regulatory wins by the UK firm Immunocore pave the way for other treatments deploying TCRs. TCRs have become a hot topic in immuno-oncology. Many companies are developing cancer […]

April 6, 2022 - 3 minutesmins - By Jonathan Smith

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

United Kingdom

Duke Street Bio enters stage with next-generation cancer therapies

F2G enlists Shionogi to bring antifungal treatment to Europe and Asia

The Top European Biotech Investments in April 2022

Amphista Lands Megadeals to Smash Cancer using Protein Degradation

Chief Business Officers: Shedding Light on Biotech’s Dealmakers

Denmark Recruits Lifebit to Boost Personalized Medicine with Genomics

OMass Therapeutics Takes on ‘Undruggable’ Proteins with €90M Series B

Forcefield Therapeutics Launched to Treat Heart Attacks with Protein Drugs

Cloud Computing Can Help Life Sciences Catch Up Before It’s Too Late

Valneva’s Covid-19 Vaccine Reaches UK Market with EU In Sights

Epidarex Backs UK Startup Developing Emerging Anti-Inflammatory Drugs

Immunocore Approvals Open Door for TCR Cancer Drugs

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!